CN105535627A - 一种治疗肝郁血热型多囊卵巢综合征的药物组合物 - Google Patents
一种治疗肝郁血热型多囊卵巢综合征的药物组合物 Download PDFInfo
- Publication number
- CN105535627A CN105535627A CN201610029119.0A CN201610029119A CN105535627A CN 105535627 A CN105535627 A CN 105535627A CN 201610029119 A CN201610029119 A CN 201610029119A CN 105535627 A CN105535627 A CN 105535627A
- Authority
- CN
- China
- Prior art keywords
- parts
- rhizoma
- radix
- polycystic ovarian
- ovarian syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000004185 liver Anatomy 0.000 title claims abstract description 56
- 201000010065 polycystic ovary syndrome Diseases 0.000 title claims abstract description 44
- 206010036049 Polycystic ovaries Diseases 0.000 title claims abstract description 34
- 239000000203 mixture Substances 0.000 title claims abstract description 19
- 210000004369 blood Anatomy 0.000 title abstract description 42
- 239000008280 blood Substances 0.000 title abstract description 42
- 239000003814 drug Substances 0.000 claims abstract description 49
- 238000011282 treatment Methods 0.000 claims abstract description 43
- 244000291333 Serissa japonica Species 0.000 claims abstract description 35
- 229940079593 drug Drugs 0.000 claims abstract description 24
- 241000628997 Flos Species 0.000 claims description 35
- 239000008194 pharmaceutical composition Substances 0.000 claims description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 25
- 238000002481 ethanol extraction Methods 0.000 claims description 25
- 206010037660 Pyrexia Diseases 0.000 claims description 24
- 208000027744 congestion Diseases 0.000 claims description 22
- 238000002360 preparation method Methods 0.000 claims description 20
- 239000002775 capsule Substances 0.000 claims description 17
- 239000000284 extract Substances 0.000 claims description 11
- 239000000706 filtrate Substances 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 239000003826 tablet Substances 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 7
- 230000000295 complement effect Effects 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000000469 ethanolic extract Substances 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 5
- 238000004064 recycling Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- -1 sublimed preparation Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000002662 enteric coated tablet Substances 0.000 claims description 2
- 239000007941 film coated tablet Substances 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 235000012907 honey Nutrition 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 15
- 210000001124 body fluid Anatomy 0.000 abstract description 4
- 239000010839 body fluid Substances 0.000 abstract description 4
- 241000382455 Angelica sinensis Species 0.000 abstract 1
- 244000025254 Cannabis sativa Species 0.000 abstract 1
- 241001598107 Imperata Species 0.000 abstract 1
- 241001378009 Lespedeza tomentosa Species 0.000 abstract 1
- 241000830535 Ligustrum lucidum Species 0.000 abstract 1
- 244000241838 Lycium barbarum Species 0.000 abstract 1
- 235000015459 Lycium barbarum Nutrition 0.000 abstract 1
- 240000001341 Reynoutria japonica Species 0.000 abstract 1
- 235000018167 Reynoutria japonica Nutrition 0.000 abstract 1
- 241000220317 Rosa Species 0.000 abstract 1
- 240000006694 Stellaria media Species 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 210000000952 spleen Anatomy 0.000 description 15
- 230000006870 function Effects 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 235000009508 confectionery Nutrition 0.000 description 12
- 230000001737 promoting effect Effects 0.000 description 11
- 239000000796 flavoring agent Substances 0.000 description 10
- 235000019634 flavors Nutrition 0.000 description 10
- 201000000736 Amenorrhea Diseases 0.000 description 9
- 206010001928 Amenorrhoea Diseases 0.000 description 9
- 208000019255 Menstrual disease Diseases 0.000 description 9
- 231100000540 amenorrhea Toxicity 0.000 description 9
- 230000017531 blood circulation Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 229940088597 hormone Drugs 0.000 description 7
- 239000005556 hormone Substances 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 208000011580 syndromic disease Diseases 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 230000006378 damage Effects 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 230000002124 endocrine Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 230000002175 menstrual effect Effects 0.000 description 5
- 230000005906 menstruation Effects 0.000 description 5
- 210000001672 ovary Anatomy 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 208000005171 Dysmenorrhea Diseases 0.000 description 4
- 206010013935 Dysmenorrhoea Diseases 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 201000010066 hyperandrogenism Diseases 0.000 description 4
- 230000027758 ovulation cycle Effects 0.000 description 4
- 235000014347 soups Nutrition 0.000 description 4
- 206010021033 Hypomenorrhoea Diseases 0.000 description 3
- 208000037093 Menstruation Disturbances Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 208000009205 Tinnitus Diseases 0.000 description 3
- 206010047998 Withdrawal bleed Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 206010003549 asthenia Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 210000000232 gallbladder Anatomy 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 231100000886 tinnitus Toxicity 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010020112 Hirsutism Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 208000008930 Low Back Pain Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 208000012886 Vertigo Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 208000028659 discharge Diseases 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 230000007937 eating Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000000629 knee joint Anatomy 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000004396 mastitis Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000889 vertigo Toxicity 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000019890 Amylum Nutrition 0.000 description 1
- 201000005670 Anovulation Diseases 0.000 description 1
- 206010002659 Anovulatory cycle Diseases 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000037171 Hypercorticoidism Diseases 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010047531 Visual acuity reduced Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 201000005255 adrenal gland hyperfunction Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 231100000552 anovulation Toxicity 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960000978 cyproterone acetate Drugs 0.000 description 1
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- RWYFURDDADFSHT-RBBHPAOJSA-N diane Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.C1=C(Cl)C2=CC(=O)[C@@H]3CC3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RWYFURDDADFSHT-RBBHPAOJSA-N 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 208000031424 hyperprolactinemia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 238000009592 kidney function test Methods 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 239000003953 ovulation stimulant Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/638—Ligustrum, e.g. Chinese privet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/89—Cyperaceae (Sedge family)
- A61K36/8905—Cyperus (flatsedge)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于医药技术领域,具体涉及一种治疗肝郁血热型多囊卵巢综合征的药物组合物。该药物组合物由玫瑰花、香附、当归藤、六月雪、女贞子、枸杞子、千针万线草、小雪人参、虎杖、白茅根为原料药精心制成。全方伍用具有疏肝解郁、清热泻火、化瘀散滞、养阴生津、滋补肝肾、养血和血之功效,对肝郁血热型多囊卵巢综合征有极强的针对性疗效。
Description
技术领域
本发明属于医药技术领域,具体涉及一种治疗肝郁血热型多囊卵巢综合征的药物组合物。
背景技术
多囊卵巢综合征(polycysticovariansyndrome,PCOS)是一种发病多因性、临床表现呈多态性的内分泌综合征,以慢性无排卵、高雄激素血症和卵巢多囊性改变为临床主要特征,是妇产科临床上较为常见的内分泌紊乱性疾病,在中国乃至世界都是导致生育期妇女月经紊乱最常见的原因之一。临床表现多为月经失调、卵巢呈多囊性改变,LH/FSH比值升高,肥胖、痤疮、多毛等,多囊卵巢综合征患者多不易妊娠,如果妊娠,妊娠后常会发生早期流产、妊娠期糖尿病、妊娠期高血伍病、小样儿等多样化的综合征,提高了流产的危险。并且伴随年龄的增长会出现日益明显的胰岛素抵抗、高胰岛素血症、肥胖、高脂血症、糖尿病、高血压、冠心病等代谢性并发症。
多囊卵巢综合征的发病原因尚不明确,多数医家认为多囊卵巢综合征是在诸多因素作用下,产生了一系列复杂的生理病理改变,最终导致下丘脑-垂体-卵巢轴功能失调,西医认为其病因主要与内分泌系统、神经系统失调有关,还涉及遗传、环境、免疫、心理等多方面因素。中医古典医籍中无多囊卵巢综合征的相关记载,但根据其临床表现特点可归属于“月经后期”、“月经过少”、“闭经”、“不孕”、“癥瘤”等范畴。在临床实践中,据多囊卵巢综合征患者的主诉、病史及体征,认为其发生是外感邪气、内伤七情、饮食不节、痰湿、瘀血、劳伤气血、脏器不足共同作用的结果。
目前西医治疗多囊卵巢综合征主要是应用促排卵药、避孕药及激素类药物,虽能暂时取得一定疗效,但远期疗效较差,副作用较大,不能长期应用。而中医学的多系统协同调理,多靶点共同作用,其整体观念及辨证论治在治疗多囊卵巢综合征上有着独特的优势和潜力,未见明显的毒副作用,远期疗效较为满意。因此研制效果更为显著的治疗多囊卵巢综合征的中药制剂具有重大的意义。
发明内容
为了解决上述问题,本发明旨在提供一种治疗肝郁血热型多囊卵巢综合征的药物组合物及其制备方法。
本发明的一个目的是提供一种治疗肝郁血热型多囊卵巢综合征的药物组合物。
本发明的另一个目的是提供一种治疗肝郁血热型多囊卵巢综合征的药物组合物的制备方法。
发明人结合古今先贤的理论与自己的临床经验,把西医辨病、辨因的微观检测与中医宏观辨证施治相结合,提供的一种治疗肝郁血热型多囊卵巢综合征的药物组合物,由玫瑰花、香附、当归藤、六月雪、女贞子、枸杞子、千针万线草、小雪人参、虎杖、白茅根为原料药精心制成。
本发明优选技术方案是本发明所述的药物组合物由以下重量份的原料药制成:玫瑰花5-15份、香附8-18份、当归藤7-15份、六月雪5-15份、女贞子10-20份、枸杞子10-25份、千针万线草20-40份、白茅根15-30份、小雪人参10-20份、虎杖6-15份。
本发明进一步优选技术方案是本发明所述的药物组合物由以下重量份的原料药制成:玫瑰花8-13份、香附9-15份、当归藤11-15份、六月雪8-13份、女贞子10-15份、枸杞子15-20份、千针万线草20-25份、白茅根25-30份、小雪人参10-15份、虎杖7-12份。
本发明进一步优选技术方案是本发明所述的药物组合物由以下重量份的原料药制成:玫瑰花11份、香附10份、当归藤12份、六月雪10份、女贞子15份、枸杞子15份、千针万线草22份、白茅根27份、小雪人参10份、虎杖8份。
方中:玫瑰花甘、微苦,温,主利肺脾,益肝胆,能舒肝胆之郁气,健脾调中活血降火,兼能破血消症;香附归肝、脾、三焦经,香而能窜,辛能散,微苦能降,微甘能和,与玫瑰花配伍,能解散郁气,能降肝火,能消磨积块,为君药。当归藤苦,涩,温,能补血活血,通络;六月雪淡、微辛,性凉,善健脾利湿,舒肝气活肝血;虎杖苦,酸,微寒,善清肝热泻肝火,活血散瘀,三药伍用补血活血以养肝血而解肝之郁,清肝而降肝之火利肝气,为臣药。女贞子甘、苦,凉,能养阴益肾,补气舒肝;枸杞子甘,平,润而滋补,兼能退热,专于补肾、润肺、生津、益气,为肝肾真阴不足、劳乏内热补益之要药;千针万线草甘,性平,健脾养血,补肝益肾;小雪人参甘,性平,健脾补虚,清热利湿,活血调经;白茅根甘能补脾益血,寒能凉血除内热,五药配伍滋肝而养肝体益肝阴生肝血,补肾益精而调理冲任,补脾而益气血,生精化血为佐药。诸药互相作用,具有疏肝解郁、清热泻火、化瘀散滞、养阴生津、滋补肝肾、养血和血之功效,对肝郁血热型多囊卵巢综合征有极强的针对性疗效。
进一步地,本发明所述的药物组合物中各原料药的功能及功能主治如下。
玫瑰花:【性味】甘、微苦,温。【归经】归肝、脾经。【功能主治】行气解郁,和血,止痛。用于肝胃气痛,食少呕恶,月经不调,跌扑伤痛。【功能主治】理气解郁,和血散瘀。治肝胃气痛,新久风痹,吐血咯血,月经不调,赤白带下,痢疾,乳痈,肿毒。
香附:【性味】辛、微苦、微甘,平。【归经】归肝、脾、三焦经。【功能主治】行气解郁,调经止痛。用于肝郁气滞,胸、胁、脘腹胀痛,消化不良,胸脘痞闷,寒疝腹痛,乳房胀痛,月经不调,经闭痛经。【用法用量】6~9g。《纲目》:“香附之气平而不寒,香而能窜,其味多辛能散,微苦能降,微甘能和。乃气病之总司,女科之主帅也。”
当归藤:【性味】苦;涩;性温。【归经】肝;肾经。【功能主治】补血;活血;强壮腰膝。主血虚诸证;月经不调;闭经;产后虚弱;腰腿酸痛;跌打骨折。【用法用量】内服:煎汤,15~30g。外用:适量,鲜品捣敷。
六月雪:【性味】味淡、微辛,性凉。【功能主治】健脾利湿,舒肝活血。用于小儿疳积,急慢性肝炎,经闭,白带,风湿腰痛。
虎杖:【性味】苦;酸;性微寒。【归经】肝;胆经。【功能主治】活血散瘀;祛风通络;清热利湿;解毒。主妇女经闭;痛经;产后恶露不下;症瘕积聚;跌扑损伤;风湿痹痛;湿热黄疸;淋浊带下;疮疡肿毒;毒蛇咬伤;水火烫伤。【用法用量】内服:煎汤,10-15g;或浸酒;或入丸、散。外用:适量,研末调敷;或煎浓汁湿敷;或熬膏涂擦。
女贞子:【性味】甘、苦,凉。【归经】归肝、肾经。【功能主治】滋补肝肾,明目乌发。用于眩晕耳鸣,腰膝酸软,须发早白,目暗不明。《本草再新》:“养阴益肾,补气舒肝。治腰腿疼,通经和血。”
枸杞子:【性味】甘,平。【归经】归肝、肾经。【功能主治】滋补肝肾,益精明目。用于虚劳精亏,腰膝酸痛,眩晕耳鸣,内热消渴,血虚萎黄,目昏不明。本草经疏》:“枸杞子,润而滋补,兼能退热,而专于补肾、润肺、生津、益气,为肝肾真阴不足、劳乏内热补益之要药。”
千针万线草:【性味】甘;性平。【归经】肝;脾;肾经。【功能主治】健脾养血;补肝益肾;消肿。主贫血;精神短少;头晕心慌;耳鸣眼花;潮热;遗精;月经不调;带下;骨折;乳腺炎。【用法用量】内服:煎汤,15-30g;或炖肉服。外用:适量,鲜品捣敷。
小雪人参:【性味】甘;微淡;性平。【归经】脾经。【功能主治】健脾补虚;清热利湿;活血调经。主虚劳;血虚头晕;水肿;腹水;痢疾;经闭;痛经。【用法用量】内服:煎汤,15-30g。
白茅根:【性味】甘,寒。【归经】归肺、胃、膀胱经。【功能主治】凉血止血,清热利尿。用于血热吐血,衄血,尿血,热病烦渴,黄疸,水肿,热淋涩痛;急性肾炎水肿。《本草求原》:白茅根,和上下之阳,清脾胃伏热,生肺津以凉血,为热血妄行上下诸失血之要药。
为了更好地表达本发明的药物组合物,本发明的药物组合物可由玫瑰花、香附、当归藤、六月雪、虎杖、女贞子、枸杞子、千针万线草、小雪人参、白茅根或其水或其有机溶剂提取物为活性成分,加入药学上可接受的辅料或辅助性成分制备成药学上常用的剂型。
所述的药学上可接受的载体或辅助性成分,如淀粉、糖粉、糊精、微晶纤维、可压性淀粉、微粉硅胶、果糖、羧甲基淀粉钠、羧甲基纤维素钠、羟丙基甲基纤维素、植物油、卵磷脂、聚乙二醇、丙二醇、尼泊金乙酯、磷脂类材料、高岭土、滑石粉、硬脂酸钙、硬脂酸镁、聚乙烯吡咯烷酮、甘油、土温80、琼脂、碳酸钙、碳酸氢钙,等等。
其中,所述的剂型优选为口服剂型,比如:片剂、薄膜衣片剂、肠溶衣片剂、胶囊剂、硬胶囊剂、软胶囊剂、口服液、颗粒剂、蜜丸剂、散剂、丹剂、溶液剂等。
优选地,上述所述的药物组合物优选制成片剂、胶囊剂或颗粒剂,最优选为胶囊剂。
本发明还提供了该药物组合物的制备方法,它包括如下步骤:将玫瑰花、香附、六月雪、虎杖加75%的乙醇提取二次,每次1.5-2.0小时,收集乙醇提取液及乙醇提取物滤渣,减压浓缩成干浸膏,冷冻干燥,粉碎得乙醇提取物;将当归藤、女贞子、枸杞子、千针万线草、小雪人参、白茅根连同玫瑰花、香附、六月雪、虎杖乙醇提取物滤渣加水煎煮二次,合并煎液,滤过,滤液减压浓缩至相对密度为1.05-1.10(60℃测得),加入乙醇使含醇量达35%,于0-10℃静置12小时,滤过,滤液回收乙醇后减压浓缩成干浸膏,粉碎后与玫瑰花、香附、六月雪、虎杖乙醇提取物混匀,该成分单独或与药物可接受的载体或辅助性成分混合,依照制剂学常规技术制成。
本发明还请求保护上述药物组合物在制备治疗肝郁血热型多囊卵巢综合征的药物中的用途。在临床观察过程中,经过本发明药物治疗三个疗程的PCOS患者,参照《中药新药临床研究指导原则》判定标准PCOS疗效,治疗病例71例,显效41例,有效28例,无效2例,显效率57.7%,总有效率97.2%,观察组与对照组显效率、总有效率比较,差异有统计学意义(P<0.05),说明观察组较对照组可以明显的提高多囊卵巢综合征患者的临床治愈率及显效率;观察组治疗前后LH/FSH、T值比较均有极其显著性差异(P<0.01),与对照组治疗后比较,差异有统计学意义(P<0.05)。详述如下。
1资料与方法
1.1一般资料:观察2014年1月至2015年1月就诊于我院妇科门诊确诊为肝郁血热型多囊卵巢综合征的患者142例,随机分为观察组与对照组进行观察,每组71例。观察组年龄16-27岁,平均年龄22.3±3.1岁,病程最长3.5年,最短6个月,平均1.65±0.68年。对照组年龄16-26岁,平均21.9±2.9岁;病程最长3.5年,最短5个月,平均1.56±0.51年。两组一般资料比较无统计学差异(P>0.05),具有可比性。
1.2诊断标准:
1.2.1多囊卵巢综合征诊断标注:参照2003年鹿特丹PCOS会议修订的标准:(1)月经稀发或闭经;(2)临床和(或)生化指标提示存在高雄激素血症(高雄激素血症的临床表现包括痤疮、多毛);(3)超声提示多囊卵巢:一侧或双侧卵巢有≥12个直径在2-9mm的小卵泡,和(或)卵巢体积增大>10mL。以上(1)-(3)具备任意2个或3个者可诊断多囊卵巢综合征。
1.2.2中医辨证标准参:考参考中华人民共和国卫生部制定《中华人民共和国国家标准·中医临床诊疗术语症候部分》、《中药新药治疗月经不调的临床研究指导原则》以及普通高等教育中医药规划教材《中医妇科学》第七版教材,结合实际拟定证候诊断标准,如下:肝郁血热型:主证:月经先后不定或周期紊乱,经量少或闭经,经色紫黯;次证:经夹血块或痛经,经前乳房胀痛,情志不畅,心烦易怒,口苦咽干;舌脉:舌红,边有瘀点,苔薄黄,脉弦数。具各主证之一项,次证两项或以上,加舌脉方可诊断。
1.3纳入及排除标准:
1.3.1纳入标准:同时符合西医诊断标准和中医辨证标准,并签署知情同意书。
1.3.2排除标准:辨证不符合肝郁血热证者;合并可引起高雄激素血症的其他疾病,如先天性肾上腺皮质增生、库欣综合征和肿瘤者;合并高泌乳素血症、糖尿病、甲状腺功能异常等内分泌疾病者;近3个月曾接受性激素或影响脂类代谢的药物治疗者;对本研究药物过敏者;不能配合治疗及观察者。
1.4治疗方法:
观察组:口服本发明实施例1制备的胶囊,每日2次,每次2-4粒,饭后半小时服用。一个月经周期为一疗程,逢经期停用,共治疗3个疗程。
对照组:于自然月经或撤退性出血第5天开始口服达英-35(每片含醋酸环丙孕酮2mg和炔雌醇35μg),每日1片,连服21天),停药后待撤退性出血第5天起重复服用,共3个疗程。
两组患者在治疗期间均不服用其他药物,耐心向患者解释病情,消除患者心理顾虑,嘱患者精神乐观,劳逸适度,忌食生冷及辛辣。
1.5观察指标:
1.5.1观察治疗前、治疗3个周期后及停药后第3个周期患者的月经改善情况(主要询问患者月经来潮时间,月经量、色、质情况)。
1.5.2于月经来潮或撤退性出血3~5d,清晨空腹静脉抽血,分别测定血清性激素(卵泡刺激素(FSH)、黄体生成素(LH)、睾酮(T))水平;
1.5.3治疗前后检测肝功能水平,以观察两组的毒副反应情况。
1.6疗效标准:参照《中药新药临床研究指导原则》标准拟订。显效:月经周期恢复正常,停药后月经规则连续>3个周期,临床症状明显减轻,基础体温双相,生理激素水平基本正常,B超提示卵巢恢复正常大小;有效:月经周期基本恢复正常,停药后3个周期病情偶有复发,临床症状有所减轻,生理激素水平趋于正常,B超提示卵巢较治疗前有所缩小;无效:月经紊乱,甚或仍然闭经,临床症状及生理激素水平无明显改善,B超检查无明显改善。
总有效率=(显效例数+有效例数)/总例数×100%。
1.7统计学方法:采用SPSS15.0统计软件进行计算。各数值以表示,计量资料采用t检验,计数资料采用χ2检验,以P<0.05为差异有统计学意义。
2结果
临床观察过程中无退出、无脱落病例,全部完成临床观察。
2.1两组患者多囊卵巢综合征疗效比较:治疗后观察组显效41例,有效28例,无效2例,显效率57.7%,总有效率97.2%;对照组显效22例,有效34例,无效15例,显效率31.0%,总有效率78.9%,观察组与对照组显效率、总有效率比较,差异有统计学意义(P<0.05),说明观察组较对照组可以明显的提高多囊卵巢综合征患者的临床治愈率及显效率。见表1。
表1两组患者疗效比较(n%,例)
组别 | 人数 | 显效 | 有效 | 无效 | 显效率% | 总有效率% |
观察组 | 71 | 41 | 28 | 2 | 59.2%* | 97.4%* |
对照组 | 71 | 22 | 34 | 15 | 31.0% | 78.9% |
注:与对照组比较,*P<0.05。
2.2两组血清内分泌激素指标比较:治疗前两组患者血清内分泌激素各项指标比较,无显著性差异(P>0.05)。治疗后,两组患者T、LH、FSH血清内分泌激素水平均有下降。治疗组治疗前后LH/FSH、T值比较均有极其显著性差异(P<0.01)。对照组治疗前后LH/FSH、T值比较有显著性差异(P<0.05),治疗后两组间比较,差异有统计学意义(P<0.05)。见表2。
表2两组血清内分泌激素指标比较
注:与治疗前比较,*P<0.05,**P<0.01,治疗后与对照组比较,#P<0.05。
2.3安全性观察两组患者治疗前后肝功能、肾功能检查均无异常。观察组服药期间无明显不适,对照组16例出现药物不良反应,如突破性出血、体重轻度增加、乳胀、头晕,未经特殊处理,症状逐渐消失。故相比于西药常规疗法,本发明药物应用于肝郁血热型多囊卵巢综合征患者的临床疗效更佳,疗效值得肯定,在临床治疗中应加以推广应用。
本发明相对与现有技术,有如下明显优势:首先,本发明药物组合物组方主要是依据肝郁血热型多囊卵巢综合征的病机特点研制而成,有极强的针对性疗效。
本发明组方精简,配伍合理,成本低廉,经临床应用验证,其疗效确切,药性平和,未出现毒副作用及明显不良反应,安全系数高。
本发明中药制剂采用先进提取设备和工艺,充分提取有效成分,可制成方便口服或携带的中药制剂,如片剂、胶囊剂或颗粒剂。
具体实施方式
以下通过具体实施例进一步描述本发明,本发明不仅仅限于以下实施例。在本发明的范围内或者在不脱离本发明的内容、精神和范围内,对本发明进行的变更、组合或替换,对于本领域的技术人员来说是显而易见的,且包含在本发明的范围之内。
实施例1胶囊剂
处方:玫瑰花11份、香附10份、当归藤12份、六月雪10份、女贞子15份、枸杞子15份、千针万线草22份、白茅根27份、小雪人参10份、虎杖8份。
制备方法:将玫瑰花、香附、六月雪、虎杖加75%的乙醇提取二次,每次1.5-2.0小时,收集乙醇提取液及乙醇提取物滤渣,减压浓缩成干浸膏,冷冻干燥,粉碎得乙醇提取物;将当归藤、女贞子、枸杞子、千针万线草、小雪人参、白茅根连同玫瑰花、香附、六月雪、虎杖乙醇提取物滤渣加水煎煮二次,合并煎液,滤过,滤液减压浓缩至相对密度为1.05-1.10(60℃测得),加入乙醇使含醇量达35%,于0-10℃静置12小时,滤过,滤液回收乙醇后减压浓缩成干浸膏,粉碎后与玫瑰花、香附、六月雪、虎杖乙醇提取物混匀,依照制剂学常规技术制成胶囊剂。
本实施例制得的胶囊剂,每粒含有生药1.4g。
实施例2胶囊剂
处方:玫瑰花10份、香附15份、当归藤15份、六月雪12份、女贞子10份、枸杞子20份、千针万线草20份、白茅根25份、小雪人参12份、虎杖10份。
制备方法:参照实施例1的操作。
实施例3胶囊剂
处方:玫瑰花5份、香附10份、当归藤8份、六月雪10份、女贞子10份、枸杞子15份、千针万线草30份、白茅根20份、小雪人参15份、虎杖10份。
制备方法:参照实施例1的操作。
实施例4胶囊剂
处方:玫瑰花10份、香附15份、当归藤10份、六月雪8份、女贞子12份、枸杞子18份、千针万线草25份、白茅根25份、小雪人参12份、虎杖15份。
制备方法:参照实施例1的操作。
实施例5胶囊剂
处方:玫瑰花13份、香附10份、当归藤15份、六月雪15份、女贞子20份、枸杞子10份、千针万线草30份、白茅根25份、小雪人参15份、虎杖6份。
制备方法:参照实施例1的操作。
实施例6胶囊剂
处方:玫瑰花10份、香附12份、当归藤15份、六月雪5份、女贞子20份、枸杞子15份、千针万线草25份、白茅根30份、小雪人参10份、虎杖12份。
制备方法:参照实施例1的操作。
实施例7颗粒剂
处方:玫瑰花12份、香附12份、当归藤10份、六月雪15份、女贞子18份、枸杞子15份、千针万线草25份、白茅根27份、小雪人参10份、虎杖8份。
制备方法:
将玫瑰花、香附、六月雪、虎杖加75%的乙醇提取二次,每次1.5-2.0小时,收集乙醇提取液及乙醇提取物滤渣,减压浓缩成干浸膏,冷冻干燥,粉碎得乙醇提取物;将当归藤、女贞子、枸杞子、千针万线草、小雪人参、白茅根连同玫瑰花、香附、六月雪、虎杖乙醇提取物滤渣加水煎煮二次,合并煎液,滤过,滤液减压浓缩至相对密度为1.05-1.10(60℃测得),加入乙醇使含醇量达35%,于0-10℃静置12小时,滤过,滤液回收乙醇后减压浓缩成干浸膏,粉碎后与玫瑰花、香附、六月雪、虎杖乙醇提取物混匀,该成分单独或与药物可接受的载体或辅助性成分混合,依照制剂学常规技术制成颗粒剂。
本实施例制得的胶囊剂,每粒含有生药3.0g。
实施例8片剂
处方:玫瑰花15份、香附18份、当归藤15份、六月雪15份、女贞子15份、枸杞子25份、千针万线草32份、白茅根27份、小雪人参10份、虎杖10份。
制备方法:将玫瑰花、香附、六月雪、虎杖加75%的乙醇提取二次,每次1.5-2.0小时,收集乙醇提取液及乙醇提取物滤渣,减压浓缩成干浸膏,冷冻干燥,粉碎得乙醇提取物;将当归藤、女贞子、枸杞子、千针万线草、小雪人参、白茅根连同玫瑰花、香附、六月雪、虎杖乙醇提取物滤渣加水煎煮二次,合并煎液,滤过,滤液减压浓缩至相对密度为1.05-1.10(60℃测得),加入乙醇使含醇量达35%,于0-10℃静置12小时,滤过,滤液回收乙醇后减压浓缩成干浸膏,粉碎后与玫瑰花、香附、六月雪、虎杖乙醇提取物混匀,该成分单独或与药物可接受的载体或辅助性成分混合,依照制剂学常规技术制成片剂。
本实施例制得的片剂,每片含有生药1.2g。
Claims (10)
1.一种治疗肝郁血热型多囊卵巢综合征的药物组合物,其特征在于由玫瑰花、香附、当归藤、六月雪、女贞子、枸杞子、千针万线草、小雪人参、虎杖、白茅根为原料药制成。
2.如权利要求1所述的治疗肝郁血热型多囊卵巢综合征的药物组合物,其特征在于由以下优选重量份的原料药制成:玫瑰花5-15份、香附8-18份、当归藤7-15份、六月雪5-15份、女贞子10-20份、枸杞子10-25份、千针万线草20-40份、白茅根15-30份、小雪人参10-20份、虎杖6-15份。
3.如权利要求2所述的治疗肝郁血热型多囊卵巢综合征的药物组合物,其特征在于由以下优选重量份的原料药制成:玫瑰花8-13份、香附9-15份、当归藤11-15份、六月雪8-13份、女贞子10-15份、枸杞子15-20份、千针万线草20-25份、白茅根25-30份、小雪人参10-15份、虎杖7-12份。
4.如权利要求3所述的治疗肝郁血热型多囊卵巢综合征的药物组合物,其特征在于由以下优选重量份的原料药制成:玫瑰花11份、香附10份、当归藤12份、六月雪10份、女贞子15份、枸杞子15份、千针万线草22份、白茅根27份、小雪人参10份、虎杖8份。
5.如权利要求1-4任一所述的治疗肝郁血热型多囊卵巢综合征的药物组合物,其特征在于制备方法包括如下步骤:将玫瑰花、香附、六月雪、虎杖加75%的乙醇提取二次,每次1.5-2.0小时,收集乙醇提取液及乙醇提取物滤渣,减压浓缩成干浸膏,冷冻干燥,粉碎得乙醇提取物;将当归藤、女贞子、枸杞子、千针万线草、小雪人参、白茅根连同玫瑰花、香附、六月雪、虎杖乙醇提取物滤渣加水煎煮二次,合并煎液,滤过,滤液减压浓缩至相对密度为1.05-1.10(60℃测得),加入乙醇使含醇量达35%,于0-10℃静置12小时,滤过,滤液回收乙醇后减压浓缩成干浸膏,粉碎后与玫瑰花、香附、六月雪、虎杖乙醇提取物混匀,该成分单独或与药物可接受的载体或辅助性成分混合,依照制剂学常规技术制成。
6.如权利要求1-4任一所述的治疗肝郁血热型多囊卵巢综合征的药物组合物,其特征在于所述的药物组合物制成为口服剂型,比如:片剂、薄膜衣片剂、肠溶衣片剂、胶囊剂、硬胶囊剂、软胶囊剂、口服液、颗粒剂、蜜丸剂、散剂、丹剂、溶液剂等。
7.如权利要求6所述的治疗肝郁血热型多囊卵巢综合征的药物组合物,其特征在于所述口服剂型优选为片剂、胶囊剂或颗粒剂。
8.如权利要求7所述的治疗肝郁血热型多囊卵巢综合征的药物组合物,其特征在于所述口服剂型优选为胶囊剂。
9.如权利要求1-4任一所述的的药物组合物在制备治疗肝郁血热型多囊卵巢综合征的药物中的用途。
10.如权利要求1-4任一所述的的药物组合物在制备治疗多囊卵巢综合征的药物中的用途。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610029119.0A CN105535627A (zh) | 2016-01-18 | 2016-01-18 | 一种治疗肝郁血热型多囊卵巢综合征的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610029119.0A CN105535627A (zh) | 2016-01-18 | 2016-01-18 | 一种治疗肝郁血热型多囊卵巢综合征的药物组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105535627A true CN105535627A (zh) | 2016-05-04 |
Family
ID=55815517
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610029119.0A Withdrawn CN105535627A (zh) | 2016-01-18 | 2016-01-18 | 一种治疗肝郁血热型多囊卵巢综合征的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105535627A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104162094A (zh) * | 2014-05-05 | 2014-11-26 | 中国人民解放军第二军医大学 | 一种治疗肥胖型多囊卵巢综合征的中药组合物及其药物制剂 |
CN105168625A (zh) * | 2015-08-31 | 2015-12-23 | 陈红 | 一种临床护理上用于治疗二、三期褥疮的中药涂膜剂 |
-
2016
- 2016-01-18 CN CN201610029119.0A patent/CN105535627A/zh not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104162094A (zh) * | 2014-05-05 | 2014-11-26 | 中国人民解放军第二军医大学 | 一种治疗肥胖型多囊卵巢综合征的中药组合物及其药物制剂 |
CN105168625A (zh) * | 2015-08-31 | 2015-12-23 | 陈红 | 一种临床护理上用于治疗二、三期褥疮的中药涂膜剂 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102205107B (zh) | 一种治疗十二指肠溃疡的中药制剂及其制备方法 | |
CN104162094A (zh) | 一种治疗肥胖型多囊卵巢综合征的中药组合物及其药物制剂 | |
CN102600423A (zh) | 用于治疗肝纤维化的中药制备方法 | |
CN104958607A (zh) | 一种治疗妇女更年期灼口综合征的中药组合物及方法 | |
CN106214964A (zh) | 安神的中药制剂 | |
CN101953936B (zh) | 一种治疗免疫性血小板减少性紫癜的中药制剂及其制备方法 | |
CN105412787A (zh) | 治疗产后月经不调的药物 | |
CN103948782B (zh) | 一种治疗肝郁气滞型乳腺增生的药物组合物及其制备方法和用途 | |
CN104524071A (zh) | 一种治疗原发性肾病的药物组合物及其用途 | |
CN102048913B (zh) | 一种治疗更年期综合症的中药制剂及其制备方法 | |
CN115252753A (zh) | 治疗失眠的中药组合物及其应用 | |
CN103191399A (zh) | 用于治疗支气管哮喘急性发作期的中药组合物 | |
CN105497262A (zh) | 一种治疗肝肾阴虚型多囊卵巢综合征的药物组合物 | |
CN104784472A (zh) | 一种降血糖治疗糖尿病的中药组合物 | |
CN108853340A (zh) | 一种滋养肝肾的中药及其制备方法 | |
CN105535627A (zh) | 一种治疗肝郁血热型多囊卵巢综合征的药物组合物 | |
CN105833013A (zh) | 一种治疗甲状腺癌术后复发甲状腺结节的药物组合物 | |
CN105597020A (zh) | 一种治疗多囊卵巢综合征合并乳腺增生的药物组合物 | |
CN105770520A (zh) | 一种用于治疗冠心病的药物制剂及其用途 | |
CN105535466A (zh) | 一种治疗青春期多囊卵巢综合征的药物组合物 | |
CN105395768A (zh) | 一种治疗气血两虚型月经量少的药物组合物 | |
CN105288372A (zh) | 一种治疗原发性痛经伴痤疮的药物制剂 | |
CN105535711A (zh) | 一种治疗多囊卵巢综合征伴痤疮的药物组合物 | |
CN105833031A (zh) | 一种用于甲状腺癌术后心肾阴虚证的药物组合物 | |
CN105943996A (zh) | 一种治疗甲状腺腺瘤的药物组合物及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160504 |